- Home
- DNP vs VKTX Comparison
DNP vs VKTX Comparison
Compare DNP & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- VKTX
- Stock Information
- Founded
- DNP 1986
- VKTX 2012
- Country
- DNP United States
- VKTX United States
- Employees
- DNP N/A
- VKTX N/A
- Industry
- DNP Investment Managers
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- VKTX Health Care
- Exchange
- DNP Nasdaq
- VKTX Nasdaq
- Market Cap
- DNP 3.4B
- VKTX 3.4B
- IPO Year
- DNP N/A
- VKTX 2015
- Fundamental
- Price
- DNP $9.45
- VKTX $34.07
- Analyst Decision
- DNP
- VKTX Strong Buy
- Analyst Count
- DNP 0
- VKTX 14
- Target Price
- DNP N/A
- VKTX $97.29
- AVG Volume (30 Days)
- DNP 708.8K
- VKTX 4.9M
- Earning Date
- DNP 01-01-0001
- VKTX 02-05-2025
- Dividend Yield
- DNP 8.63%
- VKTX N/A
- EPS Growth
- DNP N/A
- VKTX N/A
- EPS
- DNP N/A
- VKTX N/A
- Revenue
- DNP N/A
- VKTX N/A
- Revenue This Year
- DNP N/A
- VKTX N/A
- Revenue Next Year
- DNP N/A
- VKTX $986.87
- P/E Ratio
- DNP N/A
- VKTX N/A
- Revenue Growth
- DNP N/A
- VKTX N/A
- 52 Week Low
- DNP $8.09
- VKTX $28.64
- 52 Week High
- DNP $11.18
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- DNP 56.40
- VKTX 51.41
- Support Level
- DNP $9.20
- VKTX $28.90
- Resistance Level
- DNP $9.49
- VKTX $34.37
- Average True Range (ATR)
- DNP 0.11
- VKTX 2.37
- MACD
- DNP -0.00
- VKTX 0.66
- Stochastic Oscillator
- DNP 78.12
- VKTX 70.06
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.